Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
United States10 participantsStarted 2026-08
Plain-language summary
This research sub-study is to evaluate if combining images from Optical Coherence Tomography (OCT) scans with Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) could show a link between structural changes in the back of the eye and vision. 10 participants that were enrolled in the COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy study \[NCT05961332\] will be approached to enroll. Participants may complete OCT imaging and initial assessments during an initial visit and may return for additional procedures, including microperimetry and AOSLO imaging, within a window of up to 4 weeks.
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria (from the main study):
* 50 years or older and may be either male or female and may be of any race
* Established diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD)
* GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude participants from participation
* Willing to participate as evidenced by signing the written informed consent
Additional Sub-study Inclusion Criteria:
* Early-stage GA defined as
* GA area of between 1.25 mm2 and 23 mm2
* GA may be unifocal or multifocal
* GA may be subfoveal or extrafoveal
* Concurrent peripapillary atrophy will not exclude participant from participation
* Phakic and pseudophakic participants are eligible for enrollment, with phakic participants prioritized when feasible.
Exclusion Criteria (from the main study):
* Unable to tolerate ophthalmic imaging
* Presence of neovascular AMD on optical coherence tomography (OCT) as confirmed by an ophthalmologist
* Presence of significant media opacity preventing adequate retinal imaging
* Presence of concurrent retinal disease which may confound assessment
Additional Sub-study Exclusion Criteria:
* Ocular media opacity or other condition(s) that, in the opinion of …
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Photoreceptors in EZ absent regions
Timeframe: up to 6 hours total during one or two study visits
2
Area of EZ absent regions on AOSLO vs OCT imaging
Timeframe: up to 6 hours total during one or two study visits
3
Correlation of Retinal Sensitivity Data with EZ Status
Timeframe: up to 6 hours total during one or two study visits